Role of Chemokines in CNS Health and Pathology: a Focus on the CCL2/CCR2 and CXCL8/CXCR2 Networks

Overview

Journal J Cereb Blood Flow Metab

Publisher Sage Publications

Specialties Cardiology & Vascular Diseases
Endocrinology
Neurology

Date 2009 Nov 12

PMID 19904283

Citations 226

Authors

Bridgette D Semple

Thomas Kossmann

Maria Cristina Morganti-Kossmann

Affiliations

Soon will be listed here.

Abstract

Chemokines and their receptors have crucial roles in the trafficking of leukocytes, and are of particular interest in the context of the unique immune responses elicited in the central nervous system (CNS). The chemokine system CC ligand 2 (CCL2) with its receptor CC receptor 2 (CCR2), as well as the receptor CXCR2 and its multiple ligands CXCL1, CXCL2 and CXCL8, have been implicated in a wide range of neuropathologies, including trauma, ischemic injury and multiple sclerosis. This review aims to overview the current understanding of chemokines as mediators of leukocyte migration into the CNS under neuroinflammatory conditions. We will specifically focus on the involvement of two chemokine networks, namely CCL2/CCR2 and CXCL8/CXCR2, in promoting macrophage and neutrophil infiltration, respectively, into the lesioned parenchyma after focal traumatic brain injury. The constitutive brain expression of these chemokines and their receptors, including their recently identified roles in the modulation of neuroprotection, neurogenesis, and neurotransmission, will be discussed. In conclusion, the value of evidence obtained from the use of Ccl2- and Cxcr2-deficient mice will be reported, in the context of potential therapeutics inhibiting chemokine activity which are currently in clinical trial for various inflammatory diseases.

Citing Articles

Identification of inflammation-related genes signature to establish a prognostic model in MGMT unmethylated glioblastoma patients.

Mo Y, Fan D, Wang W, Wang S, Yan Y, Zhao Z Discov Oncol. 2025; 16(1):154.

PMID: 39932605 PMC: 11813837. DOI: 10.1007/s12672-025-01894-9.

Role of astrocytes connexins - pannexins in acute brain injury.

Tichauer J, Rovegno M Neurotherapeutics. 2025; 22(1):e00523.

PMID: 39848901 PMC: 11840357. DOI: 10.1016/j.neurot.2025.e00523.

CXCR2 immunomodulatory therapy protects against microstructural white matter injury and gait abnormalities but does not mitigate deficits of cognition in a preclinical model of cerebral palsy.

Kitase Y, Madurai N, Boyd R, Gerner G, Bibic A, McCallion A J Neurochem. 2024; 169(1):e16253.

PMID: 39680469 PMC: 11879638. DOI: 10.1111/jnc.16253.

Adverse effects of CXCR2 deficiency in mice reared under non-gnotobiotic conditions.

Garcia M, Morales M, Yang T, Holden J, Bossardet O, Palmer S Sci Rep. 2024; 14(1):26159.

PMID: 39478033 PMC: 11525579. DOI: 10.1038/s41598-024-75532-9.

Plant extracts and omega-3 supplementation modulate hippocampal oxylipin profile in response to LPS-induced neuroinflammation.

Martin M, Debenay E, Bardinet J, Peltier A, Pourtau L, Gaudout D Inflamm Res. 2024; 73(11):2023-2042.

PMID: 39340661 PMC: 11541341. DOI: 10.1007/s00011-024-01947-9.

References

Omari K, John G, Lango R, Raine C . Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia. 2005; 53(1):24-31. DOI: 10.1002/glia.20246. View

Kennedy K, Strieter R, Kunkel S, Lukacs N, Karpus W . Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J Neuroimmunol. 1999; 92(1-2):98-108. DOI: 10.1016/s0165-5728(98)00187-8. View

McTigue D, Tani M, Krivacic K, Chernosky A, Kelner G, Maciejewski D . Selective chemokine mRNA accumulation in the rat spinal cord after contusion injury. J Neurosci Res. 1998; 53(3):368-76. DOI: 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1. View

Pleines U, Stover J, Kossmann T, Trentz O, Morganti-Kossmann M . Soluble ICAM-1 in CSF coincides with the extent of cerebral damage in patients with severe traumatic brain injury. J Neurotrauma. 1998; 15(6):399-409. DOI: 10.1089/neu.1998.15.399. View

Calvo C, Yoshimura T, Gelman M, Mallat M . Production of monocyte chemotactic protein-1 by rat brain macrophages. Eur J Neurosci. 1996; 8(8):1725-34. DOI: 10.1111/j.1460-9568.1996.tb01316.x. View

Puma C, Danik M, Quirion R, Ramon F, Williams S . The chemokine interleukin-8 acutely reduces Ca(2+) currents in identified cholinergic septal neurons expressing CXCR1 and CXCR2 receptor mRNAs. J Neurochem. 2001; 78(5):960-71. DOI: 10.1046/j.1471-4159.2001.00469.x. View

Muessel M, Berman N, Klein R . Early and specific expression of monocyte chemoattractant protein-1 in the thalamus induced by cortical injury. Brain Res. 2000; 870(1-2):211-21. DOI: 10.1016/s0006-8993(00)02450-1. View

Wain J, Kirby J, Ali S . Leucocyte chemotaxis: Examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by Monocyte Chemoattractant Proteins-1, -2, -3 and -4. Clin Exp Immunol. 2002; 127(3):436-44. PMC: 1906309. DOI: 10.1046/j.1365-2249.2002.01764.x. View

Barna B, Pettay J, Barnett G, Zhou P, Iwasaki K, Estes M . Regulation of monocyte chemoattractant protein-1 expression in adult human non-neoplastic astrocytes is sensitive to tumor necrosis factor (TNF) or antibody to the 55-kDa TNF receptor. J Neuroimmunol. 1994; 50(1):101-7. DOI: 10.1016/0165-5728(94)90220-8. View

10.

Cardona A, Sasse M, Liu L, Cardona S, Mizutani M, Savarin C . Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood. 2008; 112(2):256-63. PMC: 2442740. DOI: 10.1182/blood-2007-10-118497. View

11.

Song L, Pachter J . Monocyte chemoattractant protein-1 alters expression of tight junction-associated proteins in brain microvascular endothelial cells. Microvasc Res. 2004; 67(1):78-89. DOI: 10.1016/j.mvr.2003.07.001. View

12.

Kurihara T, Warr G, Loy J, Bravo R . Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med. 1997; 186(10):1757-62. PMC: 2199145. DOI: 10.1084/jem.186.10.1757. View

13.

Harkness K, Sussman J, Davies-Jones G, Greenwood J, Woodroofe M . Cytokine regulation of MCP-1 expression in brain and retinal microvascular endothelial cells. J Neuroimmunol. 2003; 142(1-2):1-9. DOI: 10.1016/s0165-5728(03)00251-0. View

14.

Kuziel W, Morgan S, Dawson T, Griffin S, SMITHIES O, Ley K . Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci U S A. 1997; 94(22):12053-8. PMC: 23699. DOI: 10.1073/pnas.94.22.12053. View

15.

Schilling M, Strecker J, Schabitz W, Ringelstein E, Kiefer R . Effects of monocyte chemoattractant protein 1 on blood-borne cell recruitment after transient focal cerebral ischemia in mice. Neuroscience. 2009; 161(3):806-12. DOI: 10.1016/j.neuroscience.2009.04.025. View

16.

Yang W, Wang D, Richmond A . Role of clathrin-mediated endocytosis in CXCR2 sequestration, resensitization, and signal transduction. J Biol Chem. 1999; 274(16):11328-33. DOI: 10.1074/jbc.274.16.11328. View

17.

Berman J, Guida M, Warren J, Amat J, Brosnan C . Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat. J Immunol. 1996; 156(8):3017-23. View

18.

Horuk R . Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov. 2008; 8(1):23-33. DOI: 10.1038/nrd2734. View

19.

Sindern E, Niederkinkhaus Y, Henschel M, Ossege L, Patzold T, Malin J . Differential release of beta-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2001; 104(2):88-91. DOI: 10.1034/j.1600-0404.2001.104002088.x. View

20.

Wu D, LaRosa G, Simon M . G protein-coupled signal transduction pathways for interleukin-8. Science. 1993; 261(5117):101-3. DOI: 10.1126/science.8316840. View